DBV Technologies Set to Showcase at 2024 ACAAI Meeting
DBV Technologies to Participate in Upcoming ACAAI Congress
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, is excited to announce its participation in the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting this year. The meeting will take place from October 24 to 28, bringing together professionals from the field to discuss advancements and challenges in allergy treatment.
Highlight of the Meeting: The Product Theater
One of the focal points of the ACAAI meeting will be a “Product Theater” titled What Defines an Optimal Peanut Allergy Treatment? This panel will host leading experts including Drs. Shahzad Mustafa, Edwin Kim, Julia Upton, and Eleanor Garrow-Holding, CEO of Food Allergy and Anaphylaxis Connection Team (FAACT). They will exchange insights on creating effective peanut allergy treatments, with a session scheduled for Saturday, October 26, from 11:35 a.m. to 1:00 p.m. EDT.
Supporting the Allergy Community
DBV Technologies will also sponsor the 33rd Annual FIT Bowl, an engaging competition that tests the knowledge of allergy, asthma, and immunology among teams from various training programs. This event will take place on Saturday, October 26, from 5:45 p.m. to 7:45 p.m. EDT. Additionally, DBV is proud to be a Benefactor Level Corporate Council Member at the ACAAI 2024, reinforcing its dedication to advancing allergy care.
DBV Presentation at the ACAAI Meeting
Presenting at Product Theater:
DBV Technologies will play a significant role in discussing optimal treatment for peanut allergies. The company's presentation will provide critical insights into the challenges faced by those with this condition, enabling a deeper understanding of therapeutic approaches.
Details of the Presentation
- Presentation Date: Saturday, October 26
- Presentation Time: 11:35 a.m. to 1:00 p.m. EDT
- Session/location: HCC, Level 2, Exhibit Halls C & D, Product Theater #2
At the core of DBV's presentation will be the innovative Viaskin® Peanut patch, developed to help manage allergic reactions triggered by peanuts. This investigational patch delivers specific quantities of peanut protein through the skin, aiming to retrain the immune system.
About DBV Technologies
DBV Technologies stands at the forefront of developing biopharmaceutical solutions for food allergies and immunologic disorders. Recognizing that millions of individuals, particularly children, wrestle with food allergies daily, DBV is committed to deciphering the intricate nature of these conditions. The company is currently engaged in clinical trials assessing the Viaskin® Peanut patch, hoping to deliver a much-needed solution for young peanut allergy sufferers—ages 1 to 7.
The Viaskin® Peanut patch represents a significant innovation in allergy treatment, employing epicutaneous immunotherapy (EPIT™) to help desensitize individuals to allergens via their skin. Through this technique, DBV aims to change how allergic reactions are treated, moving away from traditional methods toward a more modern, personal approach to care.
Headquartered in Châtillon, France, with a strong operational presence in North America, DBV Technologies is dedicated to pioneering change in food allergy management. The company's ordinary shares are traded on Euronext Paris under the ticker symbol DBV, while its American Depository Shares (ADS), representing ordinary shares, trade on Nasdaq under the ticker DBVT.
For those interested in learning more about DBV Technologies and its impactful work, additional information is available through their official website and their active presence on social media platforms such as X (formerly Twitter) and LinkedIn.
Frequently Asked Questions
1. What is the main focus of DBV Technologies?
DBV Technologies focuses on developing treatments for food allergies, specifically using their innovative Viaskin patch technology.
2. When is the ACAAI Annual Scientific Meeting taking place?
The ACAAI Annual Scientific Meeting will occur from October 24 to 28.
3. Who are the experts presenting in the Product Theater?
The panel includes Drs. Shahzad Mustafa, Edwin Kim, Julia Upton, and Eleanor Garrow-Holding.
4. What is the purpose of the Viaskin® Peanut patch?
The Viaskin Peanut patch aims to provide a non-invasive method to reduce the risk of allergic reactions to peanuts.
5. Where can I find more information about DBV Technologies?
Additional information can be found on the DBV Technologies official website and their social media channels.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Urgent Call for Orthofix Medical Inc. Shareholders to Act Now
- Critical Insights on Franklin Resources, Inc. Allegations
- Key Insights for Customers Bancorp, Inc. Investors Facing Losses
- RRCA Accounts Management Navigates Security Breach Challenges
- DJI Challenges Pentagon's Military Connections Designation
- ARK Invest's Bold Moves in Biotech Stocks: Key Highlights
- Methode Electronics Faces Class Action: Investors Take Note
- Important Opportunities for Elanco Investors Amid Legal Action
- Toronto-Dominion Bank Faces Major Penalties for Compliance Failures
- Investigation Announced for MGP Ingredients, Inc. Shareholders
Recent Articles
- Decoding Recent Options Activity for Exxon Mobil Investors
- Chimerix Unveils New Stock Options to Boost Workforce Impact
- In-Depth Look at Charles Schwab's Recent Options Activity Surge
- Understanding Recent Options Activity in Constellation Energy
- Imperial Oil Limited's 2024 Q3 Earnings Call Insights
- Join the Class Action Against Sunlight Financial Holdings Today
- FIS Earnings Release Set for November: What to Expect
- Iris Energy Limited Faces Class Action: Key Details for Investors
- University of Phoenix Recognizes Excellence in Diversity Awards
- Investigation Initiated for MGP Ingredients, Inc. (MGPI) Investors
- Legal Proceedings and Impacts on Iris Energy Limited Investors
- Market Reactions: Bank Earnings, Oil Declines, and Gold Surges
- Flux Power Faces Compliance Challenges with Nasdaq Regulations
- Sentry Safety Solutions Expands Reach Through Tactical Acquisition
- NextEra Energy Boosts Shareholder Value with New Dividend
- Athira Pharma's Path to Compliance Amid Trading Challenges
- Dust Suppression Systems Market Forecasts Exceed USD 4 Billion
- Franklin Financial Revamps Portfolio and Keeps Dividend Steady
- Turning Rock Partners Proudly Marks Success with MedShift
- Grayscale Litecoin Trust Raises $2.9 Million Through New Shares
- Lipella Pharmaceuticals Strives to Overcome Nasdaq Challenges
- Forward Industries Implements Salary Adjustments Amid Challenges
- Rigel Resource Acquisition Corp. Updates Merger Agreement Terms
- Leadership Changes and Innovations at MiNK Therapeutics
- Walmart Settles Opioid Case: $123 Million Compensation Agreed
- OrthoPediatrics Corp Secures Executive Contracts Amid Growth
- Spirit Airlines Strengthens Financial Strategies for Stability
- Netflix Boosts Market as S&P 500 and Dow Reach New Heights
- Understanding Spousal Debt Responsibility and Protection Strategies
- Muncy Columbia Financial Corporation Sees Strong Q3 Growth
- Scorpio Tankers Plans Third Quarter Earnings Call Soon
- Insights on WEBTOON Entertainment's Recent Legal Challenges
- Permianville Royalty Trust Declares November Cash Distribution
- Scorpio Tankers Inc. Sets Date for Third Quarter Results Call
- Florida Governor's Campaign Pushes Controversial Cannabis Ads
- Powell Max Limited Reports Half-Year Financial Results
- KKR Real Estate Finance Trust Inc. Announces Preferred Stock Dividend
- Insights into Whale Activity Surrounding Royal Gold Stock
- Cross Country Healthcare's Q3 2024 Earnings Call Announcement
- Understanding Freeport-McMoRan's Significant Options Activity
- Investors Make Bold Moves with Vertex Pharmaceuticals Options
- Challenges And Changes In Michigan's Cannabis Landscape
- Investigation Initiated for MGP Ingredients, Inc. Investors
- Exploring e.l.f. Beauty's Options Trends and Future Insights
- Iris Energy Limited Faces Class Action Lawsuit Over Securities
- Bullish Trends Emerge in Palantir Technologies Options Market
- Big Options Activity Sparks Interest in VF's Future Prospects
- Exploring the Impact of 'The 1916 Project': A Documentary Review
- Federal Budget Surplus Marks Positive Economic Shift
- Arcadia Biosciences Achieves Significant Stock Milestone